Survodutide is Boehringer Ingelheim's dual GLP-1/glucagon receptor agonist. Its standout feature in the next-generation metabolic compound landscape is liver disease: Phase III LIVER trial data published in 2024 showed survodutide resolved MASH (metabolic dysfunction-associated steatohepatitis) without worsening fibrosis in 47% of patients at the highest dose versus 15% on placebo — the strongest pharmacological MASLD/MASH Phase III signal published to date.
The GLP-1/glucagon combination addresses obesity and metabolic disease from two angles. GLP-1R agonism drives appetite suppression and glycemic control — same as semaglutide. Glucagon receptor agonism drives hepatic fat oxidation directly in the liver, increases energy expenditure through thermogenesis, and reduces hepatic steatosis more directly than GLP-1 agonism alone. For MASLD specifically, the glucagon component is doing critical work: activating fat burning in the liver cells where fat is pathologically accumulating.
Survodutide differs from retatrutide (GLP-1 + GIP + glucagon) by omitting GIP receptor agonism. The result is a dual rather than triple agonist — producing meaningful but lower weight loss (~15% in Phase II obesity data) compared to retatrutide's ~28%. Where survodutide wins is in the liver disease application. Status as of May 2026: Phase III MASLD data published and strong. Phase III obesity ongoing. FDA filing expected 2026-2027 for the MASLD indication.
How it works
GLP-1 Receptor Agonism
Identical to semaglutide: central appetite suppression via hypothalamic GLP-1R, slowed gastric emptying, glucose-dependent insulin secretion, reduced glucagon secretion. This handles the appetite and glycemic aspects of metabolic disease — reducing caloric intake and improving insulin sensitivity.
Glucagon Receptor Agonism — The Liver Mechanism
Glucagon receptor activation in hepatocytes directly increases beta-oxidation of fatty acids, reducing hepatic steatosis. It also increases energy expenditure via brown adipose tissue thermogenesis and promotes overall lipolysis. For MASLD: the glucagon arm targets liver fat directly rather than relying on weight loss as an intermediary. This is the mechanistic differentiator from pure GLP-1 agonists.
MASLD — Three Converging Pathways
Reduced caloric intake (GLP-1) reduces substrate for hepatic fat synthesis. Glucagon receptor activation directly oxidizes existing hepatic fat. Improved insulin sensitivity reduces insulin-driven hepatic lipogenesis. The combination produces more direct liver fat reduction than GLP-1 monotherapy — this is why the Phase III liver data outperforms semaglutide's MASLD results.
What the research shows
STUDYNew England Journal of Medicine · 2024
Survodutide for MASH — Phase III LIVER trial
Rinella ME et al.
294 adults with MASH and fibrosis. MASH resolution without fibrosis worsening: 47% (survodutide highest dose) vs. 15% (placebo). Fibrosis improvement: 34% vs. 14%. Strongest Phase III MASLD pharmacotherapy data published to date.
Up to 14.9% weight loss at 46 weeks. All doses significantly outperformed placebo. GI tolerability consistent with GLP-1 class. Phase III obesity trial ongoing.
✓47% MASH resolution without fibrosis worsening in Phase III (vs. 15% placebo) — NEJM 2024
✓~15% weight loss in Phase II obesity data
✓Glucagon-driven direct hepatic fat oxidation mechanism — well-characterized
✓GLP-1 class GI side effect profile confirmed
?UNCERTAIN
?Cardiovascular outcomes trial data (ongoing)
?Phase III obesity trial final results
?Head-to-head vs. retatrutide for MASLD and obesity
?FDA approval timeline and final label
Who is tracking this
—MASLD-focused patients and researchers: survodutide is the most promising specific liver disease compound in the investigational pipeline — tracked by anyone managing fatty liver or metabolic liver disease
—Comparison to semaglutide: semaglutide reduces liver fat via weight loss; survodutide adds direct hepatic fat oxidation — different mechanism, stronger liver outcome data
—Biohacker positioning: limited off-label access currently due to research-grade availability constraints; the main community conversation is MASLD-vs-obesity positioning vs. retatrutide
—Monitoring approach: ALT, AST, GGT, FIB-4 score, and liver ultrasound/FibroScan — the biomarkers to track for liver disease response
Common misconceptions
"Survodutide is the same as retatrutide."
REALITY
Different compounds. Retatrutide = GLP-1 + GIP + glucagon (triple). Survodutide = GLP-1 + glucagon (dual, no GIP). Retatrutide produces more weight loss (~28% vs ~15%). Survodutide has stronger specific MASLD Phase III evidence. Different tools potentially best suited to different indications.
"If it works for liver disease it must be great for all weight loss goals."
REALITY
Phase II obesity data shows ~15% weight loss — meaningful but less than tirzepatide (~20%) or retatrutide (~28%). Survodutide's specific advantage is in liver disease, not maximum weight loss. Users primarily interested in weight loss have better-evidenced options.
NEXT-GEN METABOLIC COMPOUND COMPARISON
Survodutide: GLP-1 + glucagon, strongest MASLD Phase III data, ~15% weight loss. Retatrutide: GLP-1 + GIP + glucagon, ~28% weight loss Phase III, maximum efficacy. Tirzepatide: GLP-1 + GIP, ~22% weight loss, FDA-approved. Semaglutide: GLP-1 only, ~15%, most established safety data.
AI COACH PREVIEW
I have fatty liver and elevated ALT. Does survodutide make sense and how does it compare to semaglutide?
This is exactly the question survodutide is designed for — let me map out the mechanism difference that matters most for your situation. Why survodutide vs. semaglutide for fatty liver: Semaglutide reduces liver fat primarily as a consequence of weight loss. Less caloric intake → less substrate for hepatic fat synthesis → liver fat drops. The liver benefit is real but it's indirect. Survodutide adds glucagon receptor agonism directly in hepatocytes. Glucagon activation drives beta-oxidation of fatty acids — literally burning the fat sitting in liver cells rather than waiting for systemic weight loss to clear it. The Phase III data reflects this mechanism difference: 47% MASH resolution with survodutide vs. approximately 12% with semaglutide in MASH trials. Your ALT tells the story: ALT is released when hepatocytes are damaged or inflamed. In MASLD, elevated ALT reflects ongoing liver cell injury from fat accumulation and inflammation. ALT reduction is one of the clearest early biomarkers that liver fat is clearing and inflammation is resolving. What to track: Get a baseline liver panel (ALT, AST, GGT) and FIB-4 score before starting any metabolic compound. At 12-16 weeks: repeat panel. Survodutide should produce meaningfully more ALT reduction than semaglutide alone if the glucagon mechanism is engaging properly. The important caveat: survodutide is not FDA-approved as of May 2026. Phase III data is published; filing expected 2026-2027. Access is currently research-grade or clinical trial. Are you currently on semaglutide, or are you evaluating which compound to start with?
CONTINUE IN THE APP
Open PepperLedger to track your metabolic protocol →
Free to join. No credit card. Ask the Coach about your liver health biomarkers once you're in.
Free to join · No credit card · 23-day Pro trial included